VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer

被引:118
作者
Wong, C
Wellman, TL
Lounsbury, KM
机构
[1] Univ Vermont, Coll Med, Dept Obstet & Gynecol, Burlington, VT 05405 USA
[2] Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA
关键词
D O I
10.1016/j.ygyno.2003.08.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that is elevated in epithelial ovarian cancer. Hypoxia inducible factor-1alpha (HIF-1alpha) is a transcription factor that plays a regulatory role in the expression of VEGF. Currently, there is limited information regarding VEGF and HIF-1alpha expression in epithelial ovarian cancer specimens. The objective of this study was to measure VEGF and HIF-1alpha expression in epithelial ovarian cancer samples and to compare VEGF and HIF-1alpha expression between ovarian cancer and normal ovarian tissue. Methods. Serial sections of paraffin-embedded ovarian tissues from a study group of 16 control patients and 37 patients diagnosed with epithelial ovarian cancer were analyzed for expression of VEGF and HIF-1alpha using immunohistochemistry. Results. There was a strong correlation between the average expression scores of VEGF and HIF-1alpha expression (r(2) = 0.991). There was a significant increase in expression of VEGF in stage III and IV tumors over that in controls (P < 0.005). There was also a significant increase in HIF-1alpha expression in stage III and IV tumors over that in controls (P < 0.005 and P < 0.05, respectively). Conclusion. VEGF and HIF-1alpha are both expressed in epithelial ovarian cancer. VEGF expression correlated with HIF-1alpha expression, suggesting that HIF-1alpha may contribute to the overexpression of VEGF observed in epithelial ovarian cancer. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:513 / 517
页数:5
相关论文
共 18 条
[1]  
Birner P, 2001, CLIN CANCER RES, V7, P1661
[2]  
Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
[3]   Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].
Hanahan, D ;
Folkman, J .
CELL, 1996, 86 (03) :353-364
[4]   Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF [J].
Holash, J ;
Maisonpierre, PC ;
Compton, D ;
Boland, P ;
Alexander, CR ;
Zagzag, D ;
Yancopoulos, GD ;
Wiegand, SJ .
SCIENCE, 1999, 284 (5422) :1994-1998
[5]   Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells [J].
Hu, YL ;
Tee, MK ;
Goetzl, EJ ;
Auersperg, N ;
Mills, GB ;
Ferrara, N ;
Jaffe, RB .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (10) :762-768
[6]  
Huang SY, 2002, J NATL CANCER I, V94, P1134
[7]  
Jones A, 2001, CLIN CANCER RES, V7, P1263
[8]   Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1 [J].
Liu, LX ;
Lu, HW ;
Luo, YX ;
Date, T ;
Belanger, AJ ;
Vincent, KA ;
Akita, GY ;
Goldberg, M ;
Cheng, SH ;
Gregory, RJ ;
Jiang, CW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 291 (04) :908-914
[9]  
Relf M, 1997, CANCER RES, V57, P963
[10]   HIF-1α is required for solid tumor formation and embryonic vascularization [J].
Ryan, HE ;
Lo, J ;
Johnson, RS .
EMBO JOURNAL, 1998, 17 (11) :3005-3015